Bevacizumab

177 - The development of cancer immunotherapy and its promise for treating advanced cancers

Peter Attia MD

The most frequently prescribed oncology drug, which impacts blood vessels in tumors and can prolong survival in colorectal cancer by about 4.5 months when combined with other regimens.